SDF-1 在乳腺癌患者血清中表达水平及临床意义

目的:分析SDF-1在乳腺癌患者外周血中的表达水平,探讨其临床意义。方法:Elisa法检测乳腺癌患者术前及术后血清SDF-1水平,分析其与乳腺癌临床病理特征的关系。结果:乳腺癌患者术前(69例)血清SDF-1水平明显高于正常对照组(20例)(6406.7±1302.5 pg/m L vs 5217.4±1225.7 pg/m L),有明显统计学差异(P<0.01),发生远处转移的乳腺癌患者(11例)血清SDF-1水平明显高于未发生转移者(58例)(7656.4±784.1 pg/m L vs 6169.7±1364.6 pg/m L),差异具有明显统计学意义(P<0.01)。ER及Her-2表达阳性乳腺癌的患者SDF-1水平较ER及Her-2表达阴性者低,差异亦有统计学意义(P<0.05)。结论:SDF-1可能是预测乳腺癌发生及远处转移的重要标志物。

Serum Levels of SDF-1 in Breast Cancer and its Clinical Significance

Objective:This study was conducted to investigate the value of the pretreatment circulating stromal cell derived factor-1 (SDF-1) in patients with breast carcinoma.Methods:We measured SDF-1 serum concentrations and evaluated the relationship between serum SDF-1 and clinical factors in preoperative and postoperative breast cancer patients.Results:Serum levels of SDF-1 is higher in breast cancer patients than in controls (P <0.01), Serum levels of SDF-1 is higher in metastatic patients than non-metastatic patients (P <0.01 ). Serum levels of SDF-1 is higher in ER and Her-2 positive breast cancer patients than ER and Her-2 negative patients (P <0.05).Conclusion:SDF-1 might serve as a possible marker predicting development or distant metastasis in breast cancer.